Artikel
Effectiveness and tolerability of Vertigoheel for the treatment of vertigo related to arteriosclerosis in general clinical practice
Wirksamkeit und Verträglichkeit von Vertigoheel bei routinenmäßiger Behandlung älterer Erwachsener mit arteriosklerotisch bedingtem Schwindel in der Allgemeinen Praxis
Suche in Medline nach
Autoren
-
Elfi Seeger-Schellerhoff
- Porta Westfalica, Germany
-
Marinella Corgiolu
- Biologische Heilmittel Heel GmbH, Baden-Baden, Germany
| Veröffentlicht: | 10. September 2009 |
|---|
Gliederung
Text
Background: The effectiveness and tolerability of the homeopathic preparation Vertigoheel for the treatment of vertigo related to arteriosclerosis was studied in daily clinical practice.
Methods: Prospective observational study in 183 German centres. Subjects were >50 years, with arteriosclerosis-related vertigo. The observation period was 9 months. Effectiveness was evaluated on symptomatic improvement (Likert scale) and on the number, duration and intensity of attacks.
Results: 2141 subjects were included in the effectiveness and the safety populations. Mean period of observation was 7.5 ±3.0 months. 67% of subjects were women. Mean age was 72.8 years. Most subjects received Vertigoheel at 3x1 tablets or 3x2 tablets daily. At the end of the observation period, 1712 patients (80.0%) reported symptomatic improvement. The mean number of daily vertigo attacks was 3.2 ±2.3 at enrolment and 1.3 ±1.5 at the last visit. 73.6% of vertigo attacks lasted >2 minutes at baseline but 25.6% at the last observation. Intensity of attacks was considered 'mild' in 18.1% of subjects at baseline; 83.1% of subjects reported 'mild' or 'no attacks' at study end. At the last recorded visit, 35.9% of patients were reported free of vertigo. 70.0% of physicians judged overall effectiveness as good/very good. Treatments were well tolerated.
Conclusions: Vertigoheel is an effective and well tolerated treatment for vertigo related to arteriosclerosis in general clinical practice.
